TABLE 2.
Characterization of clinical samples
| Virus or animal no.a | Sampleb | Titer (SK6/Macr)c | % Inhibition by heparind | Plaque sizee |
|---|---|---|---|---|
| CoBrB 476S | SK6 | 4.5/6.8 | 0 | Large |
| 5012 | Tonsil | 6.0/7.1 | 40 | Large |
| Kidney | 5.7/6.9 | 40 | Large | |
| Blood | 6.3/6.6 | 65 | Large | |
| CoBrB 476S/C1.1.1 (E2-p7-pNS2-3′) 5016 | SK6 | 4.0/6.3 | 5 | Large |
| Tonsil | 6.4/7.3 | 55 | Large | |
| Kidney | 5.0/6.6 | 55 | Large | |
| Blood | 4.9/5.7 | 80 | Large | |
| C1.1.1/CoBrB | SK6 | 6.7/5.9 | 100 | Small |
| 5020 | Tonsil | NDf | ND | ND |
| Kidney | ND | ND | ND | |
| Blood | 1.0/2.3 | 100 | Small | |
| CoBrB/C1.1.1 (Npro′-C-Erns-E1) 5024 | SK6 | 6.3/6.2 | 100 | Small |
| Tonsil | 7.5/6.9 | 95 | Small | |
| Kidney | 5.5/4.8 | 100 | Small | |
| Blood | 4.3/4.4 | 100 | Small/largeg |
a
In vitro (SK6)- or in vivo-generated (animal number) virus.
b
Tonsil and kidney samples were prepared postmortem. EDTA-treated blood, taken at day 14 p.i., was tested.
c
Titers (log10 PFU per milliliter) were measured in a plaque assay using SK6 cells or lung macrophages (Macr).
d
Percent inhibition of infection of SK6 cells by 225 μg of heparin per ml.
e
Relative plaque size observed after 2 days of growth in a plaque assay using SK6 cells. Cells were not treated with heparin.
f
ND, not determined.
g
In the blood from this animal, approximately 1:100 plaques was a large-plaque variant.